Pancreatic Cancer Trial, Recruiting NCT07324096 Sponsor: Mayo Clinic Condition: Pancreatic Cancer
Back to Pancreatic Cancer

Pancreatic Cancer Trial, Recruiting

NCT07324096
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are aged between 50 and 85 years old
  • People who have been newly diagnosed with diabetes based on blood sugar test results, where the diagnosis was made within the last 180 days (about 6 months) before joining the trial
  • People whose diabetes diagnosis, combined with certain health factors, results in a score of 3 or higher on a specific risk assessment tool used to identify people who may benefit from pancreatic cancer screening (confirm with trial site)
  • People who are willing and able to give their consent to take part in the trial, either in writing or through a remote process

Who may not be able to join:

  • People who have already been diagnosed with pancreatic ductal adenocarcinoma (a specific type of pancreatic cancer)
  • People who have a known inherited genetic condition that increases cancer risk, such as BRCA1/2 gene mutations, Lynch syndrome, or Peutz-Jeghers syndrome
  • People who have previously had surgery on their pancreas
  • People who are already being monitored for cysts on their pancreas at the time of joining the trial
  • People for whom a contrast-enhanced CT scan (a type of detailed X-ray using a special dye) would not be considered safe or appropriate based on standard medical guidelines at the time of joining

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Ajit H. Goenka, MD, Mayo Clinic in Rochester

Phone: 855-776-0015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
24 March 2026
Est. completion
24 March 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Recruitment yield (Feasibility); Imaging adherence rates (Feasibility); Blood collection success rates (Feasibility); Completeness of electronic medical record (EMR)-based follow-up (Feasibility)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov